Effects of polysubstance exposure on neonatal outcomes for infants with intrauterine opioid exposure

J Perinatol. 2020 Oct;40(10):1489-1496. doi: 10.1038/s41372-020-0717-y. Epub 2020 Jul 8.

Abstract

Objective: Quantify the effect of prenatal polysubstance exposure on neonatal outcomes compared to methadone exposure alone.

Study design: This retrospective cohort study compared infants with methadone-only exposure to methadone with additional psychoactive substances. Outcomes included time to maximum Finnegan scores, proportion requiring scheduled morphine, and length of stay (LOS).

Results: We identified 323 subjects. The median time to maximum Finnegan score was 38.0 h with 94% peaking within 96 h. Forty-five percent of methadone-only infants were started on scheduled morphine compared to 54% of polysubstance infants (p = 0.10). LOS for polysubstance-exposed infants was 1.30 times longer than infants with methadone-only exposure (95% confidence interval: 1.05, 1.60).

Conclusions: Exposure to methadone with additional psychoactive substances is associated with longer LOS, but not postnatal morphine use or peak withdrawal symptoms. Most infants experience peak withdrawal symptoms within 4 days and may not benefit from longer observation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / adverse effects
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Length of Stay
  • Methadone / therapeutic use
  • Morphine / adverse effects
  • Neonatal Abstinence Syndrome* / drug therapy
  • Neonatal Abstinence Syndrome* / epidemiology
  • Opioid-Related Disorders* / drug therapy
  • Opioid-Related Disorders* / epidemiology
  • Pregnancy
  • Retrospective Studies

Substances

  • Analgesics, Opioid
  • Morphine
  • Methadone